KFAS
SRPT icon

Keating Financial Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

Keating Financial Advisory Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54K Sell
86
-15
-15% -$284 ﹤0.01% 2028
2026
Q1 		$2.2K Buy
101
+97
+2,425% +$1.88K ﹤0.01% 1804
2025
Q4 		$86 Buy
+4
New +$84 ﹤0.01% 2133

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Keating Financial Advisory Services's SRPT Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Sarepta Therapeutics (SRPT) stake by 15% in Q2 2026, selling an estimated $284 and leaving 86 shares worth $1.54K. The position accounts for ﹤0.01% of the portfolio, ranked #2028.

Keating Financial Advisory Services first reported a position in SRPT in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.2K in Q1 2026. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Keating Financial Advisory Services held 86 shares of Sarepta Therapeutics worth $1.54K as of Q2 2026.
  • Keating Financial Advisory Services sold 15 Sarepta Therapeutics shares in Q2 2026, an estimated $284.
  • Sarepta Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2028 holding.
  • Keating Financial Advisory Services first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Sarepta Therapeutics position peaked at $2.2K in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.